Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance

Table 2 The relationships between UGP2 and CFL1 expression and the clinicopathological characteristics of PDC

Clinicopathological characteristics	Cases	UGP2			CFL1
Clinicopathological characteristics	Cases	Positive (%)	χ ²	P value	Positive (%)	χ ²	P value
Age
≤ 45 years old	22	13 (59.1)	0.004	0.949	14 (63.6)	1.301	0.254
> 45 years old	84	49 (58.3)	0.004	0.949	42 (50.0)	1.301	0.254
Gender
Male	61	30 (49.2)	5.130	0.024	31 (50.8)	0.233	0.629
Female	45	32 (71.1)	5.130	0.024	25 (55.6)	0.233	0.629
Differentiation degree
Highly differentiated	38	14 (36.8)	16.804	0.000	13 (34.2)	17.126	0.000
Moderately differentiated	35	20 (57.1)			16 (45.7)
Poorly differentiated	33	28 (84.8)			27 (81.8)
Maximum diameter
≤ 3 cm	13	5 (38.5)	4.063	0.131	4 (30.8)	3.791	0.150
3–5 cm	68	39 (57.4)			36 (52.9)
> 5 cm	25	18 (72.0)			16 (64.0)
Lymph node metastasis
No	77	38 (49.4)	9.684	0.002	33 (42.9)	11.233	0.001
Yes	29	24 (82.8)	9.684	0.002	23 (79.3)	11.233	0.001
Invasion^a
No	42	13 (31.0)	21.728	0.000	15 (35.7)	8.178	0.004
Yes	64	49 (76.6)	21.728	0.000	41 (64.1)	8.178	0.004
TNM stage
I	11	3 (27.3)	20.074	0.000	2 (18.2)	11.171	0.011
II	42	17 (40.5)			20 (47.6)
III	37	28 (75.5)			21 (56.8)
IV	16	14 (87.5)			13 (81.3)

ISSN: 1477-7819